# EDGAR Filing Document

**Accession Number:** 0002122492
**File Stem:** 0001628280-26-022569
**Filing Date:** 2026-4
**Character Count:** 10843
**Document Hash:** c9e2fbc656200c524e98cf20e114461d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628280-26-022569.hdr.sgml**: 20260401

**ACCESSION NUMBER**: 0001628280-26-022569

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 4

**CONFORMED PERIOD OF REPORT**: 20260318

**FILED AS OF DATE**: 20260401

**DATE AS OF CHANGE**: 20260401

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Patti Darren Joel
- **CENTRAL INDEX KEY:** 0002122492

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-42128
- **FILM NUMBER:** 26824688

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 55 FLEMINGTON ROAD, LEVEL 4
- **CITY:** NORTH MELBOURNE
- **NON US STATE TERRITORY:** VICTORIA
- **PROVINCE COUNTRY:** C3
- **ZIP:** 3051
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Telix Pharmaceuticals Ltd
- **CENTRAL INDEX KEY:** 0002007191
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** C3
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 55 FLEMINGTON ROAD
- **CITY:** NORTH MELBOURNE
- **STATE:** C3
- **ZIP:** 3051
- **BUSINESS PHONE:** 61 3 9093 3855

**MAIL ADDRESS:**
- **STREET 1:** 55 FLEMINGTON ROAD
- **CITY:** NORTH MELBOURNE
- **STATE:** C3
- **ZIP:** 3051

## Ex-24

![](poa-darrenpatti001.jpg)

Power of Attorney Know all by these presents, that I do hereby appoint Oliver Newman, Genevieve Ryan, Nicole Edmonds, and Heather Papaleo, with full power of substitution, re-substitution, and delegation, the undersigned's true and lawful attorney-in-fact (such person and her substitutes and delegees being referred to herein as the "Attorney-in-Fact"), with full power to act for the undersigned and in the undersigned's name, place and stead, in the undersigned's capacity as an officer, director, or stockholder of Telix Pharmaceuticals Limited (the "Company"), to: 1. Take such actions as may be necessary or appropriate to enable the undersigned to submit and file forms, schedules and other documents with the U.S. Securities and Exchange Commission ("SEC") utilizing the SEC's Electronic Data Gathering and Retrieval ("EDGAR") system. 2. Act as an account administrator for the undersigned's EDGAR account, including: (i) appoint, remove and replace account administrators, account users, technical administrators and delegated entities; (ii) maintain the security of the undersigned's EDGAR account, including modification of access codes; (iii) maintain, modify and certify the accuracy of information on the undersigned's EDGAR account dashboard; (iv) act as the EDGAR point of contact with respect to the undersigned's EDGAR account; and (v) take any other actions contemplated by Rule 10 of Regulation S-T with respect to account administrators. 3. Cause the Company to accept a delegation of authority from any of the undersigned's EDGAR account administrators and, pursuant to that delegation, authorize the Company's EDGAR account administrators to appoint, remove or replace users for the undersigned's EDGAR account. The undersigned acknowledges that: a) This Power of Attorney authorizes, but does not require, the Attorney-in-Fact to act in his or her discretion on information provided to such Attorney-in-Fact without independent verification of such information; b) Any documents prepared or executed by the Attorney-in-Fact on behalf of the undersigned pursuant to this Power of Attorney will be in such form and will contain such information as the Attorney-in-Fact, in his or her discretion, deems necessary or desirable; c) Neither the Company nor the Attorney-in-Fact assumes any liability for the undersigned's responsibility to comply with the requirements of Section 13 or Section 16 of the Exchange Act or Rule 144, any liability of the undersigned for any failure to comply with such requirements, or any liability of the undersigned for disgorgement of profits under Section 16(b) of the Exchange Act; and d) This Power of Attorney does not relieve the undersigned from responsibility for compliance with the undersigned's obligations under Section 13 or Section 16 of the Exchange Act, including, without limitation, the reporting requirements under Section 13 or Section 16 of the Exchange Act. 4. Do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5, Schedule 13D or 13G, or Form 144, complete and execute any amendment or amendments thereto, and timely file such form with the SEC and any stock exchange or similar authority.

------

![](poa-darrenpatti002.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;The undersigned hereby grants to the Attorney-in-Fact full power and authority to do and perform each and every act and thing requisite, necessary or advisable to be done in connection with the foregoing, as fully, to all intents and purposes, as the undersigned might or could do in person, hereby ratifying and confirming all that the Attorney-in-Fact, or his or her substitute or substitutes, shall lawfully do or cause to be done by authority of this Power of Attorney. This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 or 5 or Schedules 13D or 13G or Forms 144 with respect to the undersigned's holdings of and transactions in securities of the Company, unless earlier revoked by the undersigned in a signed writing delivered to the Attorney-in-Fact. This Power of Attorney revokes all previous powers of attorney with respect to the subject matter of this Power of Attorney. IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 5th day of March, 2026. /s/ Darren Joel Patti Signature Print Name: Darren Joel Patti

------

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Patti Darren Joel<br><sub>(Last) (First) (Middle)</sub><br>C/O TELIX PHARMACEUTICALS LTD<br>55 FLEMINGTON RD<br><sub>(Street)</sub><br>NORTH MELBOURNE, AUSTRALIA 3051<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>Telix Pharmaceuticals Ltd [ TLX ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2026-03-18 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [ ] 10% Owner<br>[X] Officer (give title below)   [ ] Other (specify below)<br>_Group Chief Operating Officer_ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |
| Ordinary Shares | 25558 | D |  |
| American Depositary Receipts<sup>(1)</sup> | 804 | D |  |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Performance Share Appreciation Rights (right to buy) | <sup>(2)</sup> | 2027-04-04 | Ordinary Shares | 15826 | 4.95<sup>(3)</sup> | D |  |
| Share Rights | <sup>(4)</sup> | 2028-01-11 | Ordinary Shares | 15000 | $0 | D |  |
| Share Rights | <sup>(5)</sup> | 2027-03-12 | Ordinary Shares | 12541 | $0 | D |  |
| Performance Share Appreciation Rights (right to buy) | <sup>(6)</sup> | 2027-12-21 | Ordinary Shares | 27448 | 6.90<sup>(3)</sup> | D |  |
| Share Rights | <sup>(7)</sup> | 2029-01-11 | Ordinary Shares | 15000 | $0 | D |  |

---

### Footnotes:

(1) Each American Depositary Receipt (ADR) is convertible at any time, at the holders election, into one ordinary share of the issuer. The ADRs have no expiration date.

(2) The performance share appreciation rights (PSARs) were granted on April 5, 2022, and became vested and excercisable on March 6, 2025.

(3) Conversion price is reported in Australian Dollars.

(4) The share rights (SRs) were granted on November 1, 2023 and will become vested and exercisable on November 1, 2026, subject to continued service with the issuer. Each SR represents the contingent right to receive one ordinary share.

(5) The SRs were granted on March 18, 2026 and will become auto-vested and exercised in approximately February or March 2027. The SRs are subject to forfeiture where employment is terminated for cause only.  The vesting date will be communicated to the reporting person following testing that will occur after the audited calendar year 2026 financial results announcement. Each SR represents the contingent right to receive one ordinary share (or ADR). See footnote (1).

(6) The PSARs were granted on May 2, 2023, and became vested and exercisable on March 12, 2026.

(7) The SRs were granted on November 1, 2023 and will become vested and exercisable on November 1, 2027, subject to continued service with the issuer. Each SR represents the contingent right to receive one ordinary share.

**Remarks:**
Ex. 24 - Power of Attorney

**Signature:** /s/ Oliver Newman, on behalf of Dr. Darren Patti, Group COO  
**Date:** 2026-04-01

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**